[1]钟志辉,林焱斌,庄 研,等.骨肉瘤组织ACTN4和CD133的表达及其影响因素[J].福建医药杂志,2021,43(05):117-120.
　ZHONG Zhihui,LIN Yanbin,ZHUANG Yan,et al.Expression and interfering factors of ACTN4 and CD133 in osteosarcoma[J].FUJIAN MEDICAL JOURNAL,2021,43(05):117-120.
点击复制

骨肉瘤组织ACTN4和CD133的表达及其影响因素()
分享到：

《福建医药杂志》[ISSN:1002-2600/CN:35-1071/R]

卷:
43
期数:
2021年05期
页码:
117-120
栏目:
基础研究
出版日期:
2021-10-15

文章信息/Info

Title:
Expression and interfering factors of ACTN4 and CD133 in osteosarcoma
文章编号:
1002-2600(2021)05-0117-04
作者:
钟志辉; 林焱斌1; 庄 研; 尤龙木; 陈小霞; 吴春玲
厦门大学附属福州第二医院骨科(福州 350007)
Author(s):
ZHONG Zhihui; LIN Yanbin; ZHUANG Yan; YOU Longmu; CHEN Xiaoxia; WU Chunling
Department of Orthopedics,the Affiliated Fuzhou Municipal Second Hospital,Xiamen University,Fuzhou,Fujian 350007,China
关键词:
骨肉瘤;  α-辅肌动蛋白;  CD133;  肿瘤干细胞
Keywords:
osteosarcoma;  α-actinin-4;  CD133;  cancer stem cells
分类号:
R738.1
文献标志码:
B
摘要:
目的 观察α-辅肌动蛋白(α-actinin-4,ACTN4)和CD133在骨肉瘤组织中的表达情况,并探讨影响两者表达的相关因素。方法 收集2015年1月至2018 年1月经病理确诊为骨肉瘤的50例患者临床病理资料,应用免疫组化检测ACTN4和CD133的蛋白表达情况,分析各因素不同水平间ACTN4和CD133蛋白表达的差异。结果 ACTN4在骨肉瘤组织中阳性率为58%,CD133在骨肉瘤组织中阳性率为54%,两者阳性率均高于其在骨软骨瘤组织中的表达,差异均具有统计学意义(P<0.05)。不同Enneking外科分期、肺转移之间的ACTN4表达差异有统计学意义(P<0.05)。不同Enneking外科分期、局部复发和肺转移之间的CD133表达差异有统计学意义(P<0.05)。结论 ACTN4和CD133在骨肉瘤发生、发展中具有重要作用。
Abstract:
Objective To observe the expression of α-actinin-4(ACTN4)and CD133 in osteosarcoma and to explore the related factors affecting their expression.Methods The clinicopathological data of 50 patients with osteosarcoma diagnosed by pathology from January 2015 to January 2018 were collected.The protein expression of ACTN4 and CD133 was detected by immunohistochemistry,and the differences of protein expression among different levels of various factors were further analyzed.Results The positive rates of ACTN4 and CD133 in osteosarcoma were 58% and 54%, respectively.Both positive rates were higher than their expression in osteochondroma.There were significant differences in the expression of ACTN4 between different Enneking surgical stages and lung metastasis(P<0.05).There were significant differences in the expression of CD133 between different Enneking surgical stages,local recurrence and lung metastasis(P<0.05).Conclusion ACTN4 and CD133 play an important role in the occurrence and development of osteosarcoma.

参考文献/References:

[1] Lagmay J P,Krailo M D,Dang H,et al.Outcome of patients with recurrent osteosarcoma enrolled in seven phase ii trials through children's cancer group,pediatric oncology group,and children's oncology group: learning from the past to move forward [J].J Clin Oncol,2015,34(25):3031-3038.
[2] Sayles L C,Breese M R,Koehne A L,et al.Genome-Informed targeted therapy for osteosarcoma[J].Cancer Discov,2019,9(1):46-63.
[3] Brown H K,Tellez-Gabriel M,Heymann D.Cancer stem cells in osteosarcoma [J].Cancer Lett,2017,386:189-195.
[4] Zhong Z H,Mao S F,Lin H F,et al.Comparative proteomics of cancer stem cells in osteosarcoma using ultra-high-performance liquid chromatography and Orbitrap Fusion mass spectrometer [J].Talanta,2018,178:362-368.
[5] Robin P,Singh K,Suntharalingam K.Gallium(iii)-polypyridyl complexes as anti-osteosarcoma stem cell agents[J].Chem Commun(Camb),2020,56(10):1509-1512.
[6] Honda K,Yamada T,Hayashida Y,et al.Actinin4 increases cell motility and promotes lymph node metastasis of colorectal cancer [J].Gastroenterology,2005,128(1):5162.
[7] Liu X,Chu K M.α-Actinin-4 promotes metastasis in gastric cancer [J].Lab Invest,2017,97(9):1084-1094.
[8] Jung J, Kim S, An H T, et al.α-Actinin-4 regulates cancer stem cell properties and chemoresistance in cervical cancer[J].Carcinogenesis,2020,41(7):940-949.
[9] Fukushima S,Yoshida A,Honda K,et al.Immunohistochemical actinin4 expression in infiltrating gliomas: Association with who grade and differentiation [J].Brain tumor pathology,2014,31(1):1116.
[10] Wang N,Wang Q,Tang H,et al.Direct inhibition of ACTN4 by ellagic acid limits breast cancer metastasis via regulation of β-catenin stabilization in cancer stem cells [J].J Exp Clin Cancer Res,2017,36(1):172.
[11] Huang Q, Li X, Huang Z, et al.ACTN4 promotes the proliferation, migration, metastasis of osteosarcoma and enhances its invasive ability through the NF-κB pathway [J].Pathol Oncol Res,2020,26(2):893-904.
[12] Tirino V,Desiderio V,Paino F,et al.Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo[J].FASEB J,2011,25(6):2022-2030.
[13] 洪峰,袁高乐,张辉洁,等.微管不稳定蛋白和CD133在骨肉瘤组织的表达及其临床意义[J].中华实验外科杂志,2017,34(3):516-518.
[14] Xu N,Kang Y,Wang W,et al.The prognostic role of CD133 expression in patients with osteosarcoma[J].Clin Exp Med,2020,20(2):261-267.
[15] Zhang Y Y,Tabataba H, Liu X Y, et al.ACTN4 regulates the stability of RIPK1 in melanoma [J].Oncogene,2018,37(29):4033-4045.

相似文献/References:

[1]林文韬 王武炼 肖莉莉 张怡元.基于GEO数据库发现骨肉瘤关键基因GMFG及其生物学功能[J].福建医药杂志,2020,42(02):112.
　LIN Wentao,WANG Wulian,XIAO Lili,et al.Identification of the key gene GMFG and its biological function in osteosarcoma based on GEO database[J].FUJIAN MEDICAL JOURNAL,2020,42(05):112.
[2]肖莉莉 刘 晖 贾春锋.基于核酸适配体的微流控芯片的构建及对循环肿瘤细胞筛选性能的测定[J].福建医药杂志,2020,42(02):119.
[3]陈康尧,顾恩毅,蔡碰德,等.H1受体拮抗剂异丙嗪对顺铂治疗骨肉瘤的影响及机制[J].福建医药杂志,2021,43(04):132.
　CHEN Kangyao,GU Enyi,CAI Pengde,et al.Efficacy and mechanism of H1 receptor antagonist promethazine on osteosarcoma treated with cisplatin[J].FUJIAN MEDICAL JOURNAL,2021,43(05):132.
[4]林东泽.shRNA沉默c-myc基因对MG-63骨肉瘤细胞c-myc/PD-L1轴的影响[J].福建医药杂志,2022,44(05):133.
[5]周子杰,张家豪,姜吉霖,等.miR-586通过SFRP1调控骨肉瘤细胞增殖、迁移、侵袭的机制研究[J].福建医药杂志,2024,46(01):115.[doi:10.20148/j.fmj.2024.01.032]

备注/Memo

备注/Memo:
基金项目:福建省自然科学基金面上项目(2020J011189)
1 通信作者,Email:lyanb32@163.com
更新日期/Last Update: 2021-10-15